Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis

Kaiyun Qin; Fenghua Zhang; Hongxia Wang; Na Wang; Hongbing Qiu; Xinzhuan Jia; Shan Gong & Zhengmao Zhang

BMB Reports 2023; 56(7): 416-416

Kaiyun Qin^1,3,#, Fenghua Zhang^2,#, Hongxia Wang¹, Na Wang¹, Hongbing Qiu⁴, Xinzhuan Jia^1,5, Shan Gong¹ & Zhengmao Zhang^1,*

¹Department of Gynecology, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011, ²Department of Breast & Thyroid Surgery, Hebei General Hospital, Hebei Shijiazhuang 050057, ³Department of Gynecology, Hebei General Hospital, Hebei Shijiazhuang 050057, ⁴Department of Gynecology, Hebei Xingtai People’s Hospital, Hebei Shijiazhuang 054001, ⁵Department of Reproductive Medicine, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011, China

Correspondence to: Erratum to: BMB Reports 2023; 56(3): 184-189, PMID: 36617466, PMCID: PMC10068343
https://doi.org/10.5483/BMBRep.2022-0175

Received: June 23, 2023; Published online: July 31, 2023.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Erratum to: BMB Reports 2023; 56(3): 184-189

Body

The BMB Reports would like to correct in BMB Rep. 56(3): 184-189, titled “circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis”.

This research has the wrong affiliation of the authors and number of affiliation. Since author’s affiliation is incorrect, this information has now been corrected as follows.

Kaiyun Qin^1,3,#, Fenghua Zhang^2,#, Hongxia Wang¹, Na Wang¹, Hongbing Qiu⁴, Xinzhuan Jia^1,5, Shan Gong¹ & Zhengmao Zhang^1,*